• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

Podcast

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Curtis A. Pettaway, MD. He discusses the stigmas related to penile cancer from both the patient and physician perspectives. In addition, he highlights major developments in the space that are helping to effectively treat and normalize this disease. Pettaway is a professor of urology at the University of Texas MD Anderson Cancer Center in Houston.

Related Videos
Dr. Neal E. Rowe in an interview with Urology Times
Related Content
FDA accepts BLA for subcutaneous nivolumab in solid tumors

FDA accepts BLA for subcutaneous nivolumab in solid tumors

May 7th 2024
Article

The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.

Health policy in urology: 2024 AUA Advocacy Summit recap

Health policy in urology: 2024 AUA Advocacy Summit recap

March 21st 2024
Podcast

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

Active surveillance does not increase malpractice risk across cancers

Active surveillance does not increase malpractice risk across cancers

March 28th 2024
Article

“This data should bolster physicians’ confidence in recommending active surveillance for their patients when it is an appropriate option," says Timothy J. Daskivich, MD.

Dr. Murphy on increasing diversity in cancer clinical trials

Dr. Murphy on increasing diversity in cancer clinical trials

February 29th 2024
Podcast

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

doctor and patient sitting, facing one another

Neoadjuvant chemotherapy found safe, efficacious in penile cancer

February 21st 2024
Article

Those who experienced a response with neoadjuvant chemotherapy had a median overall survival of 73.0 months, compared with 17.0 months among non-responders.

hands of a doctor holding a patient's hand

Palliative care underutilized in malignant ureteral obstruction

January 2nd 2024
Article

Overall, 39.1% of patients with malignant ureteral obstruction were referred to palliative care over the study period.

© 2024 MJH Life Sciences

All rights reserved.